报告题目：Automation +Miniaturization = Acceleration
报告人：Alexander Dömling（帕拉茨基大学教授）
邀请人：黄良斌教授
报告时间：2026年1月16日（星期五）上午10：00—12：00
报告地点：五山校区逸夫工程馆105会议室
主办单位：化学与化工学院
报告人简介：
Prof Alexander Dömling (ERA Chair ofInnovative Chemistry Group at the Palacky University Olomouc) . He devotes hisacademic life to the design and discovery of bioactive compounds for difficulttargets such as protein protein interactions, transcription factors, or RNA. Hestudied multi-component reactions with Ivar Ugi at the Technical UniversityMunich (PhD), and with double Nobel laureate Barry Sharpless at The ScrippsResearch Institute (PD). At the University of Pittsburgh, he became associateand full professor and he introduced the “google-like” web-based technologyANCHOR.QUERY together with Carlos Camacho. ANCHOR.QUERY can screen very large(billions) of virtual compounds in just seconds for pharmacophores and based onkey interacting fragments, e.g. large amino acid side chains of amino acids (inPPIs). Interestingly the resulting virtual hits can be instantaneouslysynthesized using convergent and fast multicomponent reaction chemistry inorder to test the virtually generated hypothesis. From 2011 till 2022 he wasProfessor and chair of Drug Design at the University of Groningen. Anotherdevelopment is the technology platform Automated, miniaturized and accelerateddrug discovery (AMADEUS) which was recently rewarded by an ERC Advanced grant.Here a fundamentally novel approach towards preclinical drug discovery anddevelopment is introduced by blending Instant Chemistry, nL dispensing, HTpurification, HTS and machine learning. The indication areas Alexander Dömlingis interested in are cancer immunology, infectious diseases and metabolicdisorders. He has published more than 300 scientific articles, reviews andapplied for >70 patents. Additionally, Alexander Dömling is a serialentrepreneur trying to make the expression “from bench to bedside” become true.
报告摘要：
In my talk I will give an overview of myrecent work in organic and medicinal chemistry. My work largely focuses onisocyanide-based multicomponent reaction chemistry (IMCR). In numerouspublications I have shown the design of novel scaffolds and applications of IMCRin medicinal chemistry. I am convinced, the face of organic and medicinalchemistry will dramatically change in the next future involving robotics,automation and AI driven syntheses and property optimizations. The mantra‘Automation + Miniaturization = Acceleration’ is successfully applied in manyresearch areas and technologies, but not in synthetic chemistry, which islargely believed to be not automatable. However, with the potential toaccelerate discoveries while flattening costs, increase safety, streamline datageneration, enhance reproducibility, and lower the environmental footprint,automation and miniaturization are two promising approaches to synthesis andare worthwhile to invest in. I will introduce the concept of AMADEUS(Automated, MiniAturizeD, and acceleratEd drUg diScovery), a technologyplatform, which is able to synthesize in a fully autonomous manner thousands ofsmall molecules per day in nano- or picolitre volumes, based on hundreds ofchemistries, efficiently screened and optimized for properties using artificialintelligence.